Comparative Analysis Of The Pharmacological Evaluation Of Tridax Procumbens Whole Plant Extract: Assessing In Vitro Antidiabetic And Nephroprotective Activities And Their Impact On Glucose Uptake And Dpp-Iv Inhibition

Abstract

Through in vitro evaluations, this study explores the dual therapeutic potential of Tridax procumbens, examining its nephroprotective and antidiabetic properties. Examining the methanol extract of Tridax procumbens (TP-ME) revealed information about how it affected the dipeptidyl peptidase IV (DPP-IV) activity and how L6 myoblast cells utilised glucose.Although TP-ME had a slight antidiabetic impact, as demonstrated by a slight drop in serum levels of glucose and an upsurge in glucose absorption in L6 cells, the lack of a discernible DPP-IV inhibition calls for more research into the precise biochemical pathways at play. Concurrently, TP- ME's nephroprotective capacity is examined in relation to cytotoxicity in HEK-293 cellsinducedby cisplatin. Surprisingly, TP-ME exhibited a strong cytoprotective effect, and improving cell survival linked to kidney damage caused by cisplatin.These results highlight Tridax procumbens' potential in nephroprotective therapy by positioning it as a promising natural agent in reducing drug-induced kidney damage. Tridax procumbens presents itself as a versatile botanical candidate with potential applications in nephroprotective therapies and diabetic control. Deeper research into the precise bioactive chemicals in Tridax procumbens, their methods of action, and their potential benefits to reducing the global burden of diabetes and renal problems is warranted in light of the nuanced results seen in vitro.